



**GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE**



ulm university universität  
**uulm**



## **REPORT**

### 11th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY

**Chairs:** N. Pavlidis, GR - R. A. Stahel, CH

**Scientific Coordinators:** W. Gatzemeier, IT - R. Popescu, CH

### 5th ESO-EONS NURSING ONCOLOGY MASTERCLASS

**Chairs:** A. Margulies, CH - S. Faithfull, UK

**Scientific Coordinators:** L. Sharp, SE

17-22 March 2012

Ermatingen (Lake Constance), Switzerland

The Masterclass was held for the fourth time as a joint venture with ESMO, the European Society for Medical Oncology, for the fifth time with EONS the European Oncology Nursing Society, and for the first time as part of the Master-Online Study Program in Advanced Oncology of the University of Ulm.

## **AIMS AND OBJECTIVES**

This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme exposed participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focused on breast, gastro-intestinal, genito-urinary, gynaecological, head and neck and lung cancers. Spotlight sessions facilitated compact update on haematological diseases, therapeutic management of gliomas, cancer and pregnancy, side effects of systemic treatment, oral therapy, palliative care, cancer of unknown primary, sarcoma, and treatment of melanoma.

## **TEACHING FORMAT**

The Masterclass offered plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which concluded in take-home messages. The Clinical Sessions were complemented by Tumour Board discussions. Furthermore, participants delivered case presentations within small groups and discussed these with the chairmen and the faculty. All participants resided at the course venue and participation was compulsory throughout the course. The Masterclass was entirely in English and fluency in English was necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology attended selected medical sessions whilst the side effects, oral therapy and palliative care sessions were attended jointly.

## **THE MASTERCLASS IS:**

- A 5-day residential educational event
- Full immersion
- Clinically-oriented
- Multidisciplinary
- An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

## **CME ACCREDITATION**

The Accreditation Council for Oncology in Europe (ACOE) has recommended that the event be granted **27 European CME credits**.

The Masterclass has been furthermore accredited with **25 Category 1 ESMO MORA points**.

## **ACKNOWLEDGEMENTS**

ESO wishes to express its appreciation to **Union Bank of Switzerland (UBS)** and **Wolfsberg Centre** for their consideration and support to the 2012 Masterclass.

The Masterclass is part of the **Sharing Progress in Cancer Care (SPCC)** programme whose sustaining members are:

- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology, Merck Serono, Roche
- Silver members: Celgene Corporation, Genomic Health, Novartis Oncology and Sanofi Oncology

ESO thanks the Flims Alumni Club for the collaboration in promoting the Masterclass.

## PROGRAMME:

### 17 March

14:30 *Clinical session* **Genito-urinary cancers I**

*Chair:* K. Fizazi, FR

**Prostate cancer:**

**Local therapy: Surgery and radiotherapy**

A. Horwich, UK

**First-line endocrine treatment**

A. Horwich, UK

**Endocrine resistant - refractory**

K. Fizazi, FR

16:10 *Clinical session* **Genito-urinary cancers II**

*Chair:* K. Fizazi, FR

**Bladder cancer:**

**Neoadjuvant and adjuvant chemotherapy (locally advanced disease)**

R. Huddart, UK

**Metastatic disease: Systemic treatment**

R. Huddart, UK

**Renal cancer:**

**Metastatic renal cancer: Evidence-based treatment**

T. Eisen, UK

17:50 **Coffee break**

18:20 *Tumour board* **Genito-urinary cancers**

K. Fizazi, FR - A. Horwich, UK - T. Eisen, UK - R. Huddart, UK

20:30 **Dinner**

### 18 March

8:30 *Clinical session* **Breast cancer I**

*Chair:* G. Viale, IT

**Pathology of breast cancer**

G. Pruneri, IT

**Early systemic treatment I: Neoadjuvant**

O. Pagani, CH

**Early systemic treatment I: Neoadjuvant, surgical viewpoint**

W. Gatzemeier, IT

10:00 *Clinical session* **Breast cancer II**

*Chair:* O. Pagani, CH

**Early systemic treatment II: Adjuvant**

G. Curigliano, IT

10:45 **Coffee break**

**Treatment of metastatic breast cancer**

N. Harbeck, DE

**Radiotherapy: Key points**

J. Bernier, CH

12:15 *Tumour board* **Breast cancer**

G. Viale, IT - J. Bernier, CH - G. Curigliano, IT - W. Gatzemeier, IT

13:15 **Lunch**

14:30 **Supportive Care Session**

**Early Antiemetics**

M. Aapro, CH

**G CSF and EPO**

M. Aapro, CH

15:00 *Sponsored lecture* **Bone health in advanced cancer patients**

(SPCC lecture by Amgen)

R. von Moos, CH

15:30 *Spotlight session 1* **Haematological diseases**

M. Ghelmini, CH

16:30 **Coffee break**

17:00 *Sponsored lecture* **Management of senior ADULTS with prostate cancer - SIOG guidelines**

(SPCC lecture by Sanofi Oncology)

J. Fitzpatrick, IE

17:30 *Spotlight session 2* **Therapeutic management of gliomas**

M. Weller, CH

18:00 **Case presentations by participants**

(Genito-urinary cancers and breast cancer)

19:30 **Dinner**

## 19 March

8:30 *Clinical session* **Gynaecological cancers**

*Chair:* J. Vermorken, BE

**Ovarian cancer**

J.B. Vermorken, BE

**Cervical and endometrial cancers**

C. Sessa, CH

10:30 **Coffee break**

11:00 *Clinical session* **Head and neck cancer**

*Chair:* J. Bernier, CH

**Prognostic factors and surgical approach**

A. Dietz, DE

**Radiotherapy**

J. Bernier, CH

**Systemic therapy**

J.B. Vermorken, BE

13:00 **Lunch**

14:30 *Tumour board* **Gynaecological cancers**

J.B. Vermorken, BE - C. Sessa, CH

15:00 *Tumour board* **Head and neck cancer**

J.B. Vermorken, BE - A. Dietz, DE - C. Sessa, CH

15:30 *Sponsored lecture* **How to evaluate genomic Classifiers  
in oncology**

(SPCC lecture by Genomic Health)

S. Dirnhofer, CH

16:00 *Sponsored lecture* **The importance of the mTOR  
pathway in Breast Cancer treatment**

(SPCC lecture by Novartis)

F. André, FR

16:30 *Spotlight session 3* **Cancer and pregnancy**

N. Pavlidis, CH

17:00 **Coffee break**

17:30 **Case presentations by participants**  
(Gynaecological and head and neck cancers)

**Dinner**

19:30

## 20 March

8:30 *Clinical session* **Gastro-intestinal tumours I**

*Chair:* E. Van Cutsem, BE

**Colon cancer:**

**Adjuvant and neoadjuvant treatment of colorectal cancer**

K.H. Köhne, DE

**Systemic treatment in advanced disease**

E. Van Cutsem, BE

10:00 *Sponsored lecture* **Metastasectomies in colorectal cancer**

(SPCC lecture by Merk)

G.J. Poston, UK

10:30 **Coffee break**

11:00 *Clinical session* **Gastro-intestinal tumours II**

*Chair:* E. Van Cutsem, BE

**Management of rectal cancer (surgery and radiotherapy)**

D. Sebag-Montefiore, UK

**Systemic treatment in early and advanced gastric cancer**

C.H. Köhne, DE

12:30 *Tumour board* **Gastro-intestinal tumours**

E. Van Cutsem, BE - D. Sebag-Montefiore, UK - K.H. Köhne, DE

13:30 **Lunch**

14:30 *Sponsored lecture* **Maintenance treatment in advanced non small cell lung cancer: a new treatment paradigm?**

(SPCC lecture by Lilly)

T. Brodowicz, AT

15:00 **e-ESO online session on New accomplishments in breast cancer chemoprevention**

**A. Decensi**, Galliera Hospital, Genoa, IT

16:00 **Free time**

19:30 **Dinner**

## 21 March

8:30 *Clinical session* **Lung cancer and mesothelioma I**

*Chair:* R. Stahel, CH

**Surgery**

W. Weder, CH

**Radiotherapy**

C. Faivre-Finn, UK

**Non-small cell lung cancer systemic therapy**

R.A. Stahel, CH

10:30 **Coffee break**

11:00 *Clinical session* **Lung cancer and mesothelioma II**

*Chair:* R.A. Stahel, CH

**Small cell lung cancer**

C. Faivre-Finn, UK

**Mesothelioma**

R.A. Stahel, CH

12:00 *Tumour board* **Lung cancer**

R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK

13:00 **Lunch**

14:15 *Joint medics and nursing session* **Side effects of systemic treatment and their management**

15:15 **Cardiovascular toxicity**

A. Albini, IT

**Skin toxicity**

S. Seghaert, BE

**Neurotoxicity**

G. Cavaletti, IT

15:30 *Joint medics and nursing session* **Oral therapy: Adherence, compliance and drug interaction**

K. Redmond, CH

16:00 **Coffee break**

16:30 *Joint medics and nursing session* **Palliative care**

**Pain control**

D. Schrijvers, BE

**Advanced disease management**

A. Hoy, UK

18:00 **Learning assessment tests**

19:30 **Dinner**

## 22 March

8:30 *Spotlight session 4* **Cancer on unknown primary**

N. Pavlidis, GR

9:30 *Spotlight session 5* **Sarcoma**

P. Casali, IT

10:30 **Coffee break**

11:00 *Spotlight session 6* **Advances in systemic treatment of melanoma**

P. Patel, UK

12:00 **Closure**

## **ATTANDANCE TO THE MASTERCLASS**

Attendance to the masterclass was by application only.  
Successful applicants were granted free registration and accommodation.

**Application deadline was 1 DECEMBER 2012**

Ideal Masterclass candidate profile:

- Age between 30 and 40 years
- At least 2-3 years' experience in medical oncology or clinical oncology
- Involvement in scientific activities
- Fluency in English

APPLICATION PROCEDURE:

Candidates had to fill in the [application form](http://www.eso.net) ([www.eso.net](http://www.eso.net)) providing:

- Letter describing motivation for attending
- CV with list of publications
- Supporting letter from head of department or mentor
- Clinical case relating to one of the subjects of the Masterclass

## **COURSE STATISTICS**

Out of 135 applications 61 Participants were selected.  
The international faculty encompassed 38 members  
10 Observers from SPCC Members were present throughout the event.

## **PARTICIPANTS STATISTICS**

<b>SPECIALITY</b>	
<b>Medical Oncology</b>	35
<b>Clinical Oncology</b>	13
<b>RT Oncology</b>	2
Cancer Research	2
Gastroenterology	1
Others or not Specified	8



<b>AGE</b>	
Under 35	30
35-45	22
Over 45	3

<b>COUNTRY</b>	
<b>United Kingdom</b>	<b>7</b>
<b>Italy</b>	<b>7</b>
<b>Switzerland</b>	<b>6</b>
<b>Germany</b>	<b>4</b>
<b>Greece</b>	<b>3</b>
<b>Portugal</b>	<b>3</b>
<b>Austria</b>	<b>2</b>
<b>Brazil</b>	<b>2</b>
<b>Egypt</b>	<b>2</b>
<b>France</b>	<b>2</b>
<b>Moldova</b>	<b>2</b>
<b>Russia</b>	<b>2</b>
<b>Serbia</b>	<b>2</b>
<b>South Africa</b>	<b>2</b>
<b>Spain</b>	<b>2</b>
<b>USA</b>	<b>2</b>
<b>Canada</b>	<b>1</b>
<b>Denmark</b>	<b>1</b>
<b>Ireland</b>	<b>1</b>
<b>Lithuania</b>	<b>1</b>
<b>Poland</b>	<b>1</b>
<b>Romania</b>	<b>1</b>
<b>Slovak Republic</b>	<b>1</b>
<b>Sweden</b>	<b>1</b>
<b>The Netherlands</b>	<b>1</b>
<b>Turkey</b>	<b>1</b>
<b>Zambia</b>	<b>1</b>

#### **EVALUATION OF THE 11<sup>th</sup> MASTERCLASS IN CLINICAL ONCOLOGY**

<b>Evaluation</b>	<b>Scoring (1-4)</b>
<b>Overall rating</b>	3.54
<b>Achievement of the goals</b>	3.68
<b>Usefulness of information</b>	3.64
<b>Evidence-based teaching</b>	3.59

<b>Interaction (among faculty and participants)</b>	3.51
<b>Course facilities</b>	3.61
<b>Course organisation</b>	3.71
<b>Teaching per topic:</b>	
breast cancer	3.42
lung cancer	3.46
genito-urinary cancer	3.42
gynaecological cancer	3.40
gastro-intestinal cancer	3.52
head and neck cancer	3.34
haematological malignancies	3.52
supportive/palliative care	3.21
clinical case presentation	3.48

**Average score speakers MCO 2012: 3.34 (2.52-3.75)**



## 11th Masterclass in Clinical Oncology

Ermatingen, Switzerland - 17/22 March 2012

Evaluation questionnaire


<b>General</b>
<i>How would you rate the goals and learning outcomes of the meeting? "The Masterclass offers participants a qualified training in clinical oncology to improve their knowledge in epidemiology, prevention, diagnosis, treatment and care in the field"</i>
A) Poor: 1
B) Fair: 1
C) Good: 19
D) Excellent: 38
<i>How would you rate the goals and learning outcomes of the meeting? "Attendees improve their skills in dealing with cancer problems as a whole challenge and gain more security to intercourse with them in sense of current best clinical practice and st</i>
A) Poor: 1
B) Fair: 0
C) Good: 25
D) Excellent: 33
<i>Please give an overall rating for the quality of the education offered at this meeting</i>
A) Poor: 1
B) Fair: 0
C) Good: 16
D) Excellent: 40

### SUMMARY:

Participants appreciated the high level of this educational event and the broad opportunities for informal discussion with the faculty during sessions and beyond. Mediating oncological knowledge and principles in this way of full immersion in modern oncology created a collective spirit of teaching and learning to improving clinical skills and patient care. The evaluation of the participants opinion

(questionnaire focussing on programme objectives, programme organisation, course organisation, facilities, and faculty) indicated that the Masterclass met the needs of the participants on most of the items and highlighted the necessity of such an event. The results of this evaluation will be in particular useful to further improve the upcoming 12th Masterclass which will be held in 2013.

**The European School of Oncology (ESO)** is an independent organisation. It recognises that the industrial partners are crucial for the delivery of best cancer care and fosters the continuation of the dialogue and identification of synergies. It restrains, however, the influence of marketing and strives to maintain its independence from the sponsors with whom it interacts with a neutral approach. Since its inauguration in 1982, ESO has been promoting cancer education in Europe and abroad. The original idea of the school is to fight against cancer in optimising training and updating competence of physicians and health care workers dealing with cancer patients in providing them with a comprehensive understanding of oncology - covering all aspects from epidemiology, screening, primary and secondary prevention, molecular-biology, diagnostic procedures, interdisciplinary treatment modalities, rehabilitation, palliative care, to psycho-oncological skills and promoting the importance of controlled randomised trials in clinical oncology. ESO's mission is reflected in its motto "Learning to Care", which stresses the concept of studying and learning and also of caring for the patient in a global sense. By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from advanced research centres to daily practice, combining advanced technology with humanism in care.

A handwritten signature in black ink, appearing to read 'W. Gatzemeier', with a stylized flourish at the end.

Wolfgang Gatzemeier, M.D.  
ESO Masterclass Scientific Co-ordinator



## 11th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY

MASTERCLASS

Photo: Turn by Stephen Balkenhol - A Sculpture for Wolfberg  
Photographer: Ralph Finner, Architektur fotografie, München

# 12<sup>TH</sup> ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY

**16-21 March 2013**  
**Ermatingen (Lake Constance)**  
Switzerland

**Chairs:** N. Pavlidis, GR - R.A. Stahel, CH  
**Scientific Co-ordinators:** W. Gatzemeier, IT  
R. Popescu, CH

**The 2013 Masterclass is:**  
Held in collaboration with the  
Films Alumni Club

Part of the the Master-Online Study  
Program in Advanced Oncology of  
the University of Ulm